Antisense Oligonucleotide for Spinal Muscular Atrophy

• Conditions: Spinal Muscular Atrophy
• Interventions: Drug: Nusinersen

• Registration Number: NCT05187260
• Lead Sponsor: First Affiliated Hospital of Fujian Medical University

Brief Summary

This is a longitudinal, multiple-center, observational study of patients genetically confirmed chromosome 5q SMA to monitor the efficacy, safety, tolerability of SPINRAZA® (nusinersen) for up to 24 months.

Detailed Description

SPINRAZA® (nusinersen) is an antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Nusinersen, approved by the FDA for treatment of SMA in 2016, was approved by the Chinese National Medical Products Administration in 2019.

This is a prospective, longitudinal, multi-center, observational study designed to evaluate the efficacy, safety, tolerability and of nusinersen in patients genetically confirmed chromosome 5q SMA in China. Subjects with SMA I/II/III who are planning to initiate treatment with nusinersen will be enrolled in this study. All patients will be treated by their physicians according to standard clinical practice. SPINRAZA® (nusinersen) is administered as an intrathecal injection. A total of 5ml of cerebrospinal fluid (CSF) will be removed prior to administration of SPINRAZA® (nusinersen), which will be collected by the study. Neurofilament light chain (NfL) in CSF and blood will be assessed for the efficacy of nusinersen, as well as motor and pulmonary function.

There will be a total of nine visits. All the patients with 5q SMA receiving nusinersen will be visited face to face at baseline, day 14, day 28 and day 63 after treatment initiation, and then 4-month intervals through month 24/22.

Study Timeline

• Study First Submitted: 2021-12-25
• Study First Submitted QC: 2021-12-25
• Status Verified: 2022-01
• Study Start: 2022-01-01
• Study First Posted: 2022-01-11
• Last Update Submitted: 2022-01-11
• Last Update Posted: 2022-01-26
• Primary Completion: 2024-01-31
• Study Completion: 2024-01-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Patients genetically confirmed 5q SMA including types I, II and III, who are planning to initiate treatment with SPINRAZA® (nusinersen) as part of their clinical care plan.
• Non-5q SMA patients undergoing clinical standard lumbar puncture
• Non-SMA subjects including Asymptomatic carriers of SMA, relatives of SMA patients and carriers, and patients undergoing clinical standard lumbar puncture
• Participants or Parent(s)/legal guardian(s) willing and able to complete the informed consent process

Exclusion Criteria

• Contraindication for lumbar puncture
• Inability to access intrathecal space for nusinersen injection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
5q SMA type II	Nusinersen	-
5q SMA type I	Nusinersen	-
5q SMA type III	Nusinersen	-

Primary Outcome Measures

Name	Time	Method
Change in CSF Neurofilament Light Chain levels since baseline	up to 24months	Measured by Single-molecule Array

Secondary Outcome Measures

Name	Time	Method
Change in serum Neurofilament Light Chain levels since baseline	up to 24months	Measured by Single-molecule Array

Trial Locations

Locations (3)

Department of Neurology, Peking Union Medical College Hospital; 🇨🇳 Beijing, Beijing, China

Department of Pediatrics, Fujian Medical University Union Hospital; 🇨🇳 Fuzhou, Fujian, China

Department of Neurology, First Affiliated Hospital Fujian Medical University; 🇨🇳 Fuzhou, Fujian, China